Research. Advocacy. Support.

We advance ovarian cancer research while supporting women and their families.

Learn more about OCRFA

Know Your Risks

About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.

Learn about your risks

Latest News

  • Cediranib and its Effect on Quality of Life

    (April 26, 2017) A study recently published in Cancer evaluates the effect that cediranib, a drugs that stops the growth of new blood vessels, has on a patient’s quality of life (QOL) when used as maintenance therapy. Previous studies have shown that, for patients with relapsed epithelial ovarian cancer, cediranib used as maintenance therapy can… More

  • OCRFA Funded Study Looks at the Link Between Hypertension and Ovarian Cancer

    (April 25, 2017) Researchers from Roswell Park Cancer Institute used data from 15 different studies that were part of the Ovarian Cancer Association Consortium, partially funded by OCRFA, to examine the relationship between epithelial ovarian cancer and hypertension, heart disease, diabetes, and the medications associated with those diseases. After reviewing over 7,600 cases, it was… More

  • OCRFA Research Finds New Genetic Variants Linked to Ovarian Cancer

    A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2 mutation carriers with EOC. Researchers, including former OCRFA grantee and current OCRFA Scientific Advisory Committee Member Andrew Berchuck, looked at data from 25,509 EOC cases… More


Upcoming Events